Phocas Financial Corp. Trims Stock Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Phocas Financial Corp. trimmed its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 5.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 83,764 shares of the medical equipment provider’s stock after selling 5,227 shares during the period. Phocas Financial Corp. owned approximately 0.12% of Lantheus worth $9,193,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LNTH. Signaturefd LLC boosted its stake in Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 92 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 208 shares during the period. UMB Bank n.a. increased its holdings in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after acquiring an additional 126 shares during the period. Kathleen S. Wright Associates Inc. purchased a new stake in Lantheus in the 3rd quarter valued at $51,000. Finally, Nkcfo LLC purchased a new position in Lantheus during the 2nd quarter worth $47,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Redburn Atlantic initiated coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. JMP Securities decreased their target price on Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 7th. StockNews.com raised Lantheus from a “hold” rating to a “buy” rating in a research note on Friday, November 8th. Truist Financial reissued a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a research note on Friday, November 8th. Finally, B. Riley increased their price target on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.50.

Lantheus Stock Down 0.8 %

Shares of NASDAQ:LNTH opened at $76.22 on Tuesday. The business has a fifty day simple moving average of $104.95 and a 200-day simple moving average of $96.65. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89. The company has a market cap of $5.30 billion, a P/E ratio of 12.68 and a beta of 0.51.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.